OSE Immunotherapeutics - Another partnership win – Boehringer Ingelheim
OSE Immunotherapeutics has announced a considerable expansion of its partnership with Boehringer Ingelheim (BI), including the start of two new...
419 Views
OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle
OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is...
506 Views
OSE Immunotherapeutics - Funding accelerates Tedopi clinical development
Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public...
535 Views
OSE Immunotherapeutics - Pipeline momentum builds into FY24
OSE Immunotherapeutics’ (OSE’s) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal...
427 Views
OSE Immunotherapeutics - One step closer to key data readouts
OSE Immunotherapeutics has announced the completion of patient enrolment in its Phase II CoTikiS trial, marking another step in the clinical...
431 Views